Search results
Results from the WOW.Com Content Network
Lutetium (177 Lu) oxodotreotide or 177 Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. [5] It is a radiolabeled somatostatin analog. [3] [6] [7]
This is a list of prices of chemical elements. Listed here are mainly average market prices for bulk trade of commodities. Data on elements' abundance in Earth's crust is added for comparison. As of 2020, the most expensive non-synthetic element by both mass and volume is rhodium.
Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [5] [6] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [6] [8]
DOTA-TATE can be reacted with the radionuclides gallium-68 (T 1/2 = 68 min), lutetium-177 (T 1/2 = 6.65 d) and copper-64 (T 1/2 = 12.7 h) to form radiopharmaceuticals for positron emission tomography (PET) imaging or radionuclide therapy. 177 Lu DOTA-TATE therapy is a form of peptide receptor radionuclide therapy (PRRT) which targets ...
Radiation from lutetium (177 Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney. [45] Arginine/lysine can be used to reduce renal radiation exposure during peptide receptor radionuclide therapy with lutetium ( 177 Lu) oxodotreotide.
Forty radioisotopes have been characterized, with the most stable, besides 176 Lu, being 174 Lu with a half-life of 3.31 years, and 173 Lu with a half-life of 1.37 years. All of the remaining radioactive isotopes have half-lives that are less than 9 days, and the majority of these have half-lives that are less than half an hour.
This compound is called 177 Lu-HH1 or lutetium (177 Lu) lilotomab satetraxetan (trade name Betalutin). [1] As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway. [4] The satetraxetan structure chelating lutetium-177 [5]
Lutetium (177 Lu) chloride is a radioactive compound used for the radiolabeling of pharmaceutical molecules, aimed either as an anti-cancer therapy or for scintigraphy (medical imaging). [ 5 ] [ 6 ] It is an isotopomer of lutetium(III) chloride containing the radioisotope 177 Lu , which beta decays with a half-life of 6.64 days.